Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909852 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants
A Phase 1 study of Adalimumab, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 372
- Enrollment target
- 3
- Study locations
NCT05909852: Completed Phase 1 study of Adalimumab, sponsored by Amgen.
NCT05909852 is a Phase 1 study of Adalimumab that has completed, run by Amgen. The registered enrollment target is 372 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (520% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05909852, a Phase 1 study of Adalimumab, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 372 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the serum concentration-time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and maximum observed serum concentration (Cmax) in healthy adult participants.
Conditions Studied
Interventions
- DRUG ABP 501-HCF
- DRUG ABP 501-LCF
Study Locations (3)
California
- WCCT Global, Inc - Cypress
Florida
- Qps-Mra, Llc - South Miami
Utah
- Pharmaceutical Research Associates, Inc - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2021-07-23 |
| Est. Completion | 2021-11-24 |
| Phase | Phase 1 |
What the finished NCT05909852 record still lists
NCT05909852 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (520% higher).
The record links to 1 condition, with Adalimumab appearing as the primary indexed condition, and to 2 interventions - of which ABP 501-HCF is the first listed.
NCT05909852 reports a single indexed study location in California, Florida, Utah.
Frequently Asked Questions
What is clinical trial NCT05909852 about?
NCT05909852 is a clinical study titled "A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants". To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the serum concentration-time curve (AUC) from time 0 extrapolated to infin...
What is the current status of trial NCT05909852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 372 participants. The study started on 2021-07-23. Estimated completion is 2021-11-24.
What conditions does trial NCT05909852 study?
This clinical trial studies the following conditions: Adalimumab.
What interventions are being tested in trial NCT05909852?
The interventions under investigation include: ABP 501-HCF (DRUG), ABP 501-LCF (DRUG).
Who is sponsoring clinical trial NCT05909852?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05909852 being conducted?
This trial has 3 study locations across California, Florida, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05909852's enrollment target sits among peer trials
372 85th of 2000 higher than 1,915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI